Share on StockTwits

BioDelivery Sciences International (NASDAQ:BDSI) Director Charles Bramlage bought 1,800 shares of BioDelivery Sciences International stock in a transaction dated Friday, August 22nd. The stock was purchased at an average cost of $13.85 per share, for a total transaction of $24,930.00. Following the completion of the purchase, the director now directly owns 1,800 shares of the company’s stock, valued at approximately $24,930. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

BioDelivery Sciences International (NASDAQ:BDSI) opened at 14.26 on Tuesday. BioDelivery Sciences International has a one year low of $4.16 and a one year high of $14.44. The stock’s 50-day moving average is $13.16 and its 200-day moving average is $10.34. The company’s market cap is $703.0 million.

BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings data on Friday, August 15th. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.07) by $0.07. On average, analysts predict that BioDelivery Sciences International will post $-0.67 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on BDSI shares. Analysts at Roth Capital raised their price target on shares of BioDelivery Sciences International to $20.00 in a research note on Friday, August 8th. Separately, analysts at Ladenburg Thalmann raised their price target on shares of BioDelivery Sciences International to $21.00 in a research note on Wednesday, July 9th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $20.50.

BioDelivery Sciences International, Inc (NASDAQ:BDSI) is a specialty pharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.